Researchers at the University of Minnesota have identified microRNAs that may cause colon polyps from turning cancerous. The finding could help physicians provide more specialized, and earlier, treatment before colon cancer develops. The findings are published today in The Journal of Pathology.
The American Cancer Society estimates over 134,000 people will be diagnosed with colon cancer in 2014, despite the expanded screening processes now available. This year alone, about 50,000 people will die because of the disease.
Research was led by Subbaya Subramanian, Ph.D., assistant professor in the Division of Basic and Translational Research in the Department of Surgery in the University of Minnesota Medical School and member of the Masonic Cancer Center, University of Minnesota.
"With the advanced screenings we now have available, why are so many people still being diagnosed with colon cancer? We really wanted to understand if there was a way to stop the disease before it starts, before benign polyps became cancerous tumors," said Subramanian.
By looking at microRNA, Subramanian and his colleagues hoped to unlock what pieces were present in colon polyps that developed into cancer. They found miR-182 and miR-503 work together to transform a benign polyp to a cancerous tumor by holding down the cell's ability to create the tumor suppressing protein FBXW7.
This was determined by looking at a benign polyp cell line. In this line, miR-182 was present and appeared as a feature of the creation of adenomas, or polyps. Researchers then introduced miR-503 to the cell line and noted the partnership limited the tumor suppressing protein and polyps had a much higher potential for becoming cancerous.
Armed with this knowledge, the researchers then took a closer look at actual patient data. They examined the expression of miR-182 and miR-503 in colon cancer patients with a 12-year survival outcome data. When both microRNAs were present at higher levels, decreased patient survival was clearly correlated.
"It suggests a biomarker for colon cancer patients, something ideally physicians can one day screen for as a diagnostic and prognostic tool," said Subramanian.
Subramanian believes the next step will be determining if drugs are able to target miR-182 and -503, as well was what miR-182 and -503 do after suppressing FBXW7. He hopes to develop a clinical test as well as a translational target for treatments to be utilized in a clinical setting.
This study was supported by the Department of Surgery, University of Minnesota Medical School. Patient sets were utilized in partnership with the Mayo Clinic, Rochester, MN.
The University of Minnesota Medical School, with its two campuses in the Twin Cities and Duluth, is a leading educator of the next generation of physicians. Our graduates and the school's 3,800 faculty physicians and scientists advance patient care, discover biomedical research breakthroughs with more than $180 million in sponsored research annually, and enhance health through world-class patient care for the state of Minnesota and beyond. Visit http://www.med.umn.edu to learn more.
Masonic Cancer Center, University of Minnesota is part of the University's Academic Health Center. It is designated by the National Cancer Institute as a Comprehensive Cancer Center. For more information about the Masonic Cancer Center, visit http://www.cancer.umn.edu or call 612-624-2620.
Caroline Marin | Eurek Alert!
Decoding the genome's cryptic language
27.02.2017 | University of California - San Diego
New risk factors for anxiety disorders
24.02.2017 | Julius-Maximilians-Universität Würzburg
On January 15, 2009, Chesley B. Sullenberger was celebrated world-wide: after the two engines had failed due to bird strike, he and his flight crew succeeded after a glide flight with an Airbus A320 in ditching on the Hudson River. All 155 people on board were saved.
On January 15, 2009, Chesley B. Sullenberger was celebrated world-wide: after the two engines had failed due to bird strike, he and his flight crew succeeded...
In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport
Cells need to repair damaged DNA in our genes to prevent the development of cancer and other diseases. Our cells therefore activate and send “repair-proteins”...
The Fraunhofer IWS Dresden and Technische Universität Dresden inaugurated their jointly operated Center for Additive Manufacturing Dresden (AMCD) with a festive ceremony on February 7, 2017. Scientists from various disciplines perform research on materials, additive manufacturing processes and innovative technologies, which build up components in a layer by layer process. This technology opens up new horizons for component design and combinations of functions. For example during fabrication, electrical conductors and sensors are already able to be additively manufactured into components. They provide information about stress conditions of a product during operation.
The 3D-printing technology, or additive manufacturing as it is often called, has long made the step out of scientific research laboratories into industrial...
Nature does amazing things with limited design materials. Grass, for example, can support its own weight, resist strong wind loads, and recover after being...
13.02.2017 | Event News
10.02.2017 | Event News
09.02.2017 | Event News
27.02.2017 | Materials Sciences
27.02.2017 | Interdisciplinary Research
27.02.2017 | Life Sciences